A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer's type
Latest Information Update: 01 Jul 2024
At a glance
- Drugs Deudextromethorphan (Primary)
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- Sponsors Avanir Pharmaceuticals; Otsuka Pharmaceutical
- 18 Jan 2024 Planned End Date changed from 31 Dec 2024 to 30 Nov 2026.
- 18 Jan 2024 Planned primary completion date changed from 31 Dec 2024 to 31 Aug 2026.
- 01 Oct 2020 Status changed from not yet recruiting to recruiting.